Literature DB >> 25608111

Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.

Kirsty M Mair1, Xu Dong Yang, Lu Long, Kevin White, Emma Wallace, Marie-Ann Ewart, Craig K Docherty, Nicholas W Morrell, Margaret R MacLean.   

Abstract

RATIONALE: Major pulmonary arterial hypertension (PAH) registries report a greater incidence of PAH in women; mutations in the bone morphogenic protein type II receptor (BMPR-II) occur in approximately 80% of patients with heritable PAH (hPAH).
OBJECTIVES: We addressed the hypothesis that women may be predisposed to PAH due to normally reduced basal BMPR-II signaling in human pulmonary artery smooth muscle cells (hPASMCs).
METHODS: We examined the BMPR-II signaling pathway in hPASMCs derived from men and women with no underlying cardiovascular disease (non-PAH hPASMCs). We also determined the development of pulmonary hypertension in male and female mice deficient in Smad1.
MEASUREMENTS AND MAIN RESULTS: Platelet-derived growth factor, estrogen, and serotonin induced proliferation only in non-PAH female hPASMCs. Female non-PAH hPASMCs exhibited reduced messenger RNA and protein expression of BMPR-II, the signaling intermediary Smad1, and the downstream genes, inhibitors of DNA binding proteins, Id1 and Id3. Induction of phospho-Smad1/5/8 and Id protein by BMP4 was also reduced in female hPASMCs. BMP4 induced proliferation in female, but not male, hPASMCs. However, small interfering RNA silencing of Smad1 invoked proliferative responses to BMP4 in male hPASMCs. In male hPASMCs, estrogen decreased messenger RNA and protein expression of Id genes. The estrogen metabolite 4-hydroxyestradiol decreased phospho-Smad1/5/8 and Id expression in female hPASMCs while increasing these in males commensurate with a decreased proliferative effect in male hPASMCs. Female Smad1(+/-) mice developed pulmonary hypertension (reversed by ovariectomy).
CONCLUSIONS: We conclude that estrogen-driven suppression of BMPR-II signaling in non-PAH hPASMCs derived from women contributes to a pro-proliferative phenotype in hPASMCs that may predispose women to PAH.

Entities:  

Keywords:  bone morphogenic protein type II; estrogen; proliferation; pulmonary hypertension; sex

Mesh:

Substances:

Year:  2015        PMID: 25608111      PMCID: PMC4384779          DOI: 10.1164/rccm.201410-1802OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

1.  Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935.

Authors:  A Keegan; I Morecroft; D Smillie; M N Hicks; M R MacLean
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

2.  Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen-deficient rats.

Authors:  P S Tofovic; X Zhang; G Petrusevska
Journal:  Prilozi       Date:  2009-07

3.  Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.

Authors:  Margaret R MacLean; Graeme A Deuchar; Martin N Hicks; Ian Morecroft; Sanbing Shen; John Sheward; Janet Colston; Lynn Loughlin; Margaret Nilsen; Yvonne Dempsie; Anthony Harmar
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

4.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Authors:  E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

5.  SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension.

Authors:  Chul Han; Kwon-Ho Hong; Yong Hwan Kim; Mi-Jung Kim; Cheol Song; Myung Joon Kim; Seong-Jin Kim; Mohan K Raizada; S Paul Oh
Journal:  Hypertension       Date:  2013-03-11       Impact factor: 10.190

6.  Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels.

Authors:  Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

7.  Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.

Authors:  Yvonne Dempsie; Ian Morecroft; David J Welsh; Neil A MacRitchie; Nigel Herold; Lynn Loughlin; Margaret Nilsen; Andrew J Peacock; Anthony Harmar; Michael Bader; Margaret R MacLean
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

8.  Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.

Authors:  Kevin White; Lynn Loughlin; Zakia Maqbool; Margaret Nilsen; John McClure; Yvonne Dempsie; Andrew H Baker; Margaret R MacLean
Journal:  Physiol Genomics       Date:  2011-02-08       Impact factor: 3.107

9.  Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Authors:  Yvonne Dempsie; Margaret Nilsen; Kevin White; Kirsty M Mair; Lynn Loughlin; Noona Ambartsumian; Marlene Rabinovitch; Margaret R Maclean
Journal:  Respir Res       Date:  2011-12-20

10.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

View more
  39 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  The imitation game in pulmonary arterial hypertension. Sex, bone morphogenetic protein receptor, and the estrogen paradox.

Authors:  Sunit Singla; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2015-03-15       Impact factor: 21.405

3.  The Y Chromosome Regulates BMPR2 Expression via SRY: A Possible Reason "Why" Fewer Males Develop Pulmonary Arterial Hypertension.

Authors:  Ling Yan; Joy D Cogan; Lora K Hedges; Bethany Nunley; Rizwan Hamid; Eric D Austin
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 4.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

5.  Estrogens in Men: Another Layer of Complexity of Estradiol Metabolism in Pulmonary Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

6.  Sex and Gender Differences in Lung Disease.

Authors:  Patricia Silveyra; Nathalie Fuentes; Daniel Enrique Rodriguez Bauza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.

Authors:  Corey E Ventetuolo; Grayson L Baird; R Graham Barr; David A Bluemke; Jason S Fritz; Nicholas S Hill; James R Klinger; Joao A C Lima; Pamela Ouyang; Harold I Palevsky; Amy J Palmisciano; Ipsita Krishnan; Diane Pinder; Ioana R Preston; Kari E Roberts; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

8.  Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension.

Authors:  Pravin B Sehgal; Yang-Ming Yang; Edmund J Miller
Journal:  Mol Med       Date:  2015-07-30       Impact factor: 6.354

9.  Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.

Authors:  Steven M Kawut; Christine L Archer-Chicko; Angela DeMichele; Jason S Fritz; James R Klinger; Bonnie Ky; Harold I Palevsky; Amy J Palmisciano; Mamta Patel; Diane Pinder; Kathleen J Propert; K Akaya Smith; Frank Stanczyk; Russell Tracy; Anjali Vaidya; Mary E Whittenhall; Corey E Ventetuolo
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

10.  Pregnancy as a possible trigger for heritable pulmonary arterial hypertension.

Authors:  Maude Limoges; David Langleben; Benjamin D Fox; Roberta Shear; Paul Wieczorek; Lawrence G Rudski; Andrew M Hirsch; Robert D Schlesinger; Lyda Lesenko
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.